Dr. Pinilla-Ibarz Discusses Advancements in CML

Javier A. Pinilla-Ibarz, MD, PhD
Published: Monday, Jul 16, 2018



Javier A. Pinilla-Ibarz, MD, PhD senior member, Moffit Cancer Center, discusses the recent advances in chronic myeloid leukemia (CML). Pinilla-Ibarz says that he and colleagues do not expect much in the field after other recent advancements, but he is still surprised to see what is being concentrated on today.

One advancement in CML is the discontinuation of a drug. Pinilla-Ibarz says that there could be a lot of success there if we find out who the right patient is for this. This is a big goal for CML right now, as is the possibility of adding a second drug to tyrosine kinase inhibitors. If this is done, patients could have a deeper molecular response to treatment.


Javier A. Pinilla-Ibarz, MD, PhD senior member, Moffit Cancer Center, discusses the recent advances in chronic myeloid leukemia (CML). Pinilla-Ibarz says that he and colleagues do not expect much in the field after other recent advancements, but he is still surprised to see what is being concentrated on today.

One advancement in CML is the discontinuation of a drug. Pinilla-Ibarz says that there could be a lot of success there if we find out who the right patient is for this. This is a big goal for CML right now, as is the possibility of adding a second drug to tyrosine kinase inhibitors. If this is done, patients could have a deeper molecular response to treatment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x